Transparency Market Research in its new report titled, “Disease-modifying Anti-rheumatic Agents Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2026,” provides key insights on the disease-modifying anti-rheumatic agents market. The TMR report anticipates that the increase in obese and overweight population will drive the disease-modifying anti-rheumatic agents market during the forecast period i.e, 2018-2026. Incidence of rheumatoid arthritis is increasing across the world. According to the Centers for Disease Control and Prevention (CDC), each year, nearly 22.7% adult population, around 54.4 million, in the U.S. had some form of fibromyalgia, or lupus, gout, rheumatoid arthritis, or arthritis. The CDC also anticipates that around 26%, or 78 million, adult population in the country will have doctor-diagnosed arthritis by 2040. Obesity and overweight raise the chances of rheumatoid arthritis. According to the CDC, approximately 31% of the obese and 23% of overweight adult population report arthritis in the U.S. each year, says the report.
The report has segmented the global disease-modifying anti-rheumatic medicines market based on dosage form, distribution channel, and region. On the basis of dosage form, the market is categorized into tablet, capsule, and injection. In terms of distribution channel, the global disease-modifying anti-rheumatic medicines market is classified into retail pharmacies, online pharmacies, and hospital pharmacies. In terms of geographical perspective, the global disease-modifying anti-rheumatic agents market is categorized into Asia Pacific, Latin America, Europe, North America, and Middle East & Africa. Among these, North America held the largest market share owing to increase in health care expenditure, surge in obese and overweight population, and rise in prevalence of rheumatoid arthritis. Europe held the second largest market share in 2016 due to increase in research and development on anti-rheumatic drugs, and rise in obese and overweight adult population.
According to the report, high incidence of rheumatoid arthritis in developing countries and investment by major players in these countries with large patient population are anticipated to drive the market in Asia Pacific. The disease-modifying anti-rheumatic medicines market in Middle East & Africa is anticipated to grow at a rapid pace during the forecast period due to rise in prevalence of rheumatoid arthritis. The market in Latin America is expected to be driven by increase in awareness about rheumatoid arthritis among the people. Some of the major players in the global disease-modifying anti-rheumatic agents market are profiled in this report to give a better competitive analysis and these include Sebela Pharmaceuticals, Inc., DAVA Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB (publ)., Pfizer, Inc., Abbott Laboratories, Merck & Co., Inc. Amgen, Inc., F. Hoffmann-La Roche AG, and Janssen Biotech, Inc.
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453